CureVac

Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies

6. September 2023Antibodies

by Barbara Koegel-Hubbuch

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine

18. November 2021Clinical Data,Prophylactic Vaccines

by Barbara Koegel-Hubbuch

Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model

30. August 2021Protein Therapy

by Barbara Koegel-Hubbuch

mRNA-Based Vaccines and Mode of Action

22. Oktober 2021Mechanism of Action,Prophylactic Vaccines

by Barbara Koegel-Hubbuch

mRNA: A novel Avenue to Antibody Therapy

5. März 2019Antibodies,Review Articles

Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors

1. Juli 2019Clinical Data,Oncology,RNA Immunomodulator

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

22. März 2019Clinical Data,Prophylactic Vaccines

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

15. Februar 2019Clinical Data,Oncology

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

8. Februar 2019Clinical Data,Oncology

New Vaccine Technologies to Combat Outbreak Situations

19. September 2019Review Articles,Prophylactic Vaccines